Page header

Recommendation of the President – Ayvakyt (avapritinib)

On 6 May 2026,  the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 61/2026 on the inclusion of the medicinal product Ayvakyt (avapritinib) in the reimbursement program B.115 “Treatment of patients with systemic mastocytosis (ICD-10: C96.2, C94.3, D47.0)”

Publication in Public Information Bulletin (BIP) >>